Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| ID | DOID:1612 |
| Name | breast cancer |
| Definition | A thoracic cancer that originates in the mammary gland. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:4241 DOID:1648 |
| Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00194714 | Phase Ib/II | HER2 Vaccine | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | Completed | USA | 0 |
| NCT00313599 | Phase I | Lapatinib + Paclitaxel | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT00378638 | Phase II | Bevacizumab | Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer | Unknown status | USA | 0 |
| NCT00570323 | Phase II | Anastrozole + Fulvestrant Anastrozole | Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer | Completed | USA | 0 |
| NCT00618657 | Phase II | Carboplatin + Nab-paclitaxel + Trastuzumab Bevacizumab + Carboplatin + Nab-paclitaxel | Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | Completed | USA | 0 |
| NCT00651976 | Phase I | Letrozole | Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery | Terminated | USA | 0 |
| NCT00719875 | Phase Ib/II | Vorinostat | HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer | Completed | USA | 0 |
| NCT00733408 | Phase II | Bevacizumab + Erlotinib + Nab-paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer | Completed | USA | 0 |
| NCT00740805 | Phase I | Aldoxorubicin + Cyclophosphamide + Veliparib | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
| NCT00892736 | Phase I | Veliparib | Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy | Completed | USA | 0 |
| NCT00912340 | Phase II | Everolimus Trastuzumab | Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer | Completed | USA | 0 |
| NCT00968968 | Phase III | Trastuzumab Lapatinib + Trastuzumab | Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone | Terminated | USA | CAN | 0 |
| NCT00978250 | Phase II | 5-Fluoro-2-deoxycytidine + Tetrahydrouridine | A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) | Completed | USA | 0 |
| NCT01008150 | Phase II | Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | Completed | USA | ITA | ESP | CAN | 1 |
| NCT01035099 | Phase I | Letrozole | RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF | Completed | USA | 0 |
| NCT01037790 | Phase II | Palbociclib | PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER | Completed | USA | 0 |
| NCT01042379 | Phase II | Trilaciclib Trastuzumab Duocarmazine Cyclophosphamide + Doxorubicin Cemiplimab Amcenestrant Abemaciclib + Amcenestrant Carboplatin + Dostarlimab-gxly + HM30181A + Paclitaxel + Trastuzumab Amcenestrant + Letrozole Carboplatin + Dostarlimab-gxly + HM30181A + Paclitaxel Pertuzumab + Trastuzumab + Trilaciclib Paclitaxel + Trastuzumab Pertuzumab + Trastuzumab Cemiplimab + Fianlimab | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Recruiting | USA | 0 |
| NCT01042535 | Phase Ib/II | Ad.p53-DC vaccine + Indoximod | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer | Completed | USA | 0 |
| NCT01097278 | Phase 0 | Cholecalciferol | S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer | Completed | USA | 0 |
| NCT01106898 | Phase II | Cyclophosphamide + Paclitaxel Trastuzumab | Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery | Completed | USA | 0 |
| NCT01148849 | Phase I | Margetuximab-cmkb | Safety Study of MGAH22 in HER2-positive Carcinomas | Completed | USA | 1 |
| NCT01194869 | Phase II | Cisplatin + Paclitaxel + Sorafenib | Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer | Terminated | USA | 0 |
| NCT01216176 | Phase Ib/II | Anastrozole Saracatinib | A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | Completed | USA | 0 |
| NCT01262027 | Phase II | Dovitinib | TKI258 for Metastatic Inflammatory Breast Cancer Patients | Completed | USA | 0 |
| NCT01275677 | Phase III | Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab Cyclophosphamide + Docetaxel Cyclophosphamide + Docetaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | Active, not recruiting | USA | CAN | 2 |
| NCT01281150 | Phase I | Veliparib Paclitaxel Carboplatin | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
| NCT01283789 | Phase II | Everolimus + Lapatinib | Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer | Unknown status | USA | 0 |
| NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | GBR | 0 |
| NCT01293032 | Phase I | Tamoxifen | Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer | Completed | USA | CAN | 0 |
| NCT01300962 | Phase I | Buparlisib + Capecitabine + Lapatinib Buparlisib + Capecitabine + Trastuzumab Buparlisib + Capecitabine Alpelisib + Capecitabine | Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | Completed | USA | 0 |
| NCT01302379 | Phase I | Metformin | Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors | Completed | USA | 0 |
| NCT01310231 | Phase II | Metformin | A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer | Completed | CAN | 0 |
| NCT01320592 | Phase I | Palbociclib Paclitaxel | PD0332991/Paclitaxel in Advanced Breast Cancer | Completed | USA | 0 |
| NCT01325441 | Phase Ib/II | Napabucasin + Paclitaxel | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Completed | USA | CAN | 0 |
| NCT01340300 | Phase II | Metformin | Exercise and Metformin in Colorectal and Breast Cancer Survivors | Completed | USA | 0 |
| NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
| NCT01384253 | Phase I | 212Pb-TCMC-Trastuzumab + Trastuzumab | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | Completed | USA | 0 |
| NCT01386580 | Phase Ib/II | 2B3-101 2B3-101 + Trastuzumab | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | Completed | USA | FRA | BEL | 1 |
| NCT01401959 | Phase II | Eribulin Eribulin + Trastuzumab | Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy | Completed | USA | 0 |
| NCT01407562 | Phase I | Carboplatin Paclitaxel Pazopanib | Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT01480583 | Phase II | Trastuzumab | GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases | Completed | USA | 0 |
| NCT01501487 | FDA approved | Cyclophosphamide + Docetaxel + Doxorubicin Cyclophosphamide + Epirubicin + Fluorouracil Paclitaxel Pegfilgrastim Cyclophosphamide + Docetaxel Cyclophosphamide + Doxorubicin Carboplatin + Docetaxel + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab | MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I | Completed | USA | 0 |
| NCT01506609 | Phase II | Temozolomide + Veliparib Carboplatin + Etoposide + Veliparib Carboplatin + Paclitaxel | The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer | Completed | USA | FRA | ESP | CAN | BEL | AUS | 14 |
| NCT01517802 | Phase III | Abiraterone | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | Completed | USA | GBR | ESP | DEU | BEL | AUS | 1 |
| NCT01525589 | Phase II | Lurbinectedin | A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer | Completed | USA | ESP | 0 |
| NCT01532960 | Phase I | Poly ICLC | Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41) | Terminated | USA | 0 |
| NCT01545648 | Phase II | Denosumab | Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer | Terminated | USA | 0 |
| NCT01562873 | Phase II | Ruxolitinib | Ruxolitinib in Patients With Breast Cancer | Terminated | USA | 0 |
| NCT01570036 | Phase II | E75 Sargramostim Trastuzumab | Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | Completed | USA | 0 |
| NCT01576666 | Phase Ib/II | Buparlisib + Sonidegib | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 0 |
| NCT01596751 | Phase Ib/II | Eribulin Pexidartinib | Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer | Completed | USA | 0 |
| NCT01597388 | Phase I | Fulvestrant + Vistusertib | AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
| NCT01618357 | Phase I | Veliparib | Pre-Operative Radiation and Veliparib for Breast Cancer | Suspended | USA | 0 |
| NCT01625286 | Phase Ib/II | Capivasertib + Paclitaxel | Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients | Completed | GBR | FRA | ESP | CAN | 7 |
| NCT01640665 | Phase I | Capecitabine + Sorafenib | Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors | Completed | USA | 0 |
| NCT01650506 | Phase I | Erlotinib + Metformin | Study of Erlotinib and Metformin in Triple Negative Breast Cancer | Completed | USA | 0 |
| NCT01656538 | Phase II | Pelareorep Paclitaxel | A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | Completed | CAN | 0 |
| NCT01669343 | Phase I | Letrozole | Aromatase Inhibitor Host Factors Study | Completed | CAN | 0 |
| NCT01676753 | Phase I | Dinaciclib + Pembrolizumab | Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer | Completed | USA | 0 |
| NCT01723774 | Phase II | Palbociclib Anastrozole Goserelin | PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer | Active, not recruiting | USA | 0 |
| NCT01730833 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | Active, not recruiting | USA | 0 |
| NCT01750073 | Phase II | Doxorubicin Trastuzumab Cyclophosphamide + Paclitaxel | Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer | Active, not recruiting | USA | 0 |
| NCT01817452 | Phase II | Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (ADAPT) | Recruiting | DEU | 0 |
| NCT01831089 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | USA | ESP | 1 |
| NCT01837602 | Phase I | cMet CAR RNA T Cells Targeting Breast Cancer | Completed | USA | 0 | |
| NCT01847001 | Phase II | Propranolol Paclitaxel + Pertuzumab + Trastuzumab | Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | Completed | USA | 0 |
| NCT01853306 | Phase I | Veliparib | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | Completed | 0 | |
| NCT01862900 | Phase Ib/II | MEDI6469 | Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions | Completed | USA | 0 |
| NCT01868503 | Phase II | Lapatinib | Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer | Terminated | USA | 0 |
| NCT01870505 | Phase I | Alpelisib + Exemestane Alpelisib + Letrozole | BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer | Completed | USA | 0 |
| NCT01876251 | Phase I | Docetaxel + Nirogacestat | A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer | Terminated | USA | ITA | ESP | BEL | 0 |
| NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | ITA | GBR | ESP | CAN | 0 |
| NCT01934335 | Phase I | Vandetanib | Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer | Terminated | USA | 0 |
| NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | AUS | 1 |
| NCT01980823 | Phase I | Atorvastatin + Metformin | Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer | Completed | USA | 0 |
| NCT01989546 | Phase Ib/II | Talazoparib | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | Completed | USA | 0 |
| NCT01990209 | Phase II | Orteronel | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | Completed | USA | 0 |
| NCT01990352 | Phase II | Pegylated liposomal doxorubicin | Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy | Terminated | USA | 0 |
| NCT02000622 | Phase III | Olaparib Vinorelbine Eribulin Capecitabine | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | 14 |
| NCT02007512 | Phase II | Enzalutamide + Exemestane Exemestane | Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer | Active, not recruiting | USA | ITA | GBR | ESP | CAN | BEL | 1 |
| NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
| NCT02025803 | Phase I | Capecitabine + TAS-114 | A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT02040857 | Phase II | Exemestane Palbociclib Tamoxifen Letrozole Anastrozole | A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer | Completed | USA | 0 |
| NCT02041429 | Phase Ib/II | Paclitaxel + Ruxolitinib | Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca | Completed | USA | 0 |
| NCT02046421 | Phase I | Mifepristone Carboplatin + Gemcitabine | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
| NCT02047747 | Phase II | Dacomitinib | A Phase II Study of Dacomitinib in Progressive Brain Metastases | Terminated | USA | 0 |
| NCT02048059 | Phase II | Paclitaxel Trevatide | ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases | Completed | USA | 0 |
| NCT02051751 | Phase I | Alpelisib + Paclitaxel | A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer | Completed | USA | ITA | FRA | ESP | 0 |
| NCT02077933 | Phase I | Alpelisib + Everolimus Alpelisib + Everolimus + Exemestane | Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | Completed | USA | ITA | GBR | FRA | ESP | DEU | 3 |
| NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |
| NCT02124148 | Phase I | Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib | A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | Completed | USA | 0 |
| NCT02168777 | Phase Ib/II | Refametinib + Regorafenib Refametinib | Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer | Terminated | USA | 0 |
| NCT02202746 | Phase II | Lucitanib | A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer | Terminated | USA | 0 |
| NCT02203513 | Phase II | Prexasertib | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | Terminated | USA | 0 |
| NCT02230319 | Phase II | Paclitaxel | Prevention of Paclitaxel Neuropathy With Cryotherapy | Unknown status | USA | 0 |
| NCT02260531 | Phase II | Cabozantinib Trastuzumab | Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases | Completed | USA | 0 |
| NCT02265536 | Phase I | LY3022855 | A Study of LY3022855 In Participants With Breast or Prostate Cancer | Completed | USA | 0 |
| NCT02303990 | Phase I | Pembrolizumab | RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Completed | USA | 0 |
| NCT02307240 | Phase I | CUDC-907 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | Completed | USA | 0 |
| NCT02310464 | Phase I | OBI-821 + OBI-833 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | Completed | 1 | |
| NCT02314156 | Phase II | Telapristone acetate | Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | Completed | USA | 0 |
| NCT02366130 | Phase II | Tamoxifen Denosumab + Radium Ra 223 dichloride Fulvestrant | Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer | Completed | USA | 0 |
| NCT02379585 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Paclitaxel Docetaxel + Pertuzumab + Trastuzumab | Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer | Terminated | USA | 0 |
| NCT02384239 | Phase II | Fulvestrant + Palbociclib Palbociclib + Tamoxifen | A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | Completed | USA | 0 |
| NCT02391480 | Phase I | Mivebresib | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | Completed | USA | 0 |
| NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | 1 |
| NCT02393794 | Phase Ib/II | Cisplatin + Nivolumab + Romidepsin Cisplatin + Romidepsin | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | Active, not recruiting | USA | 0 |
| NCT02414269 | Phase I | Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | Active, not recruiting | USA | 0 |
| NCT02540330 | Phase II | Fulvestrant | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant (007) | Terminated | USA | 0 |
| NCT02563925 | Phase I | Tremelimumab | Brain Irradiation and Tremelimumab in Metastatic Breast Cancer | Completed | USA | 0 |
| NCT02564900 | Phase I | Trastuzumab deruxtecan | Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | Active, not recruiting | USA | 1 |
| NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 22 |
| NCT02576665 | Phase I | Toca 511 + Toca FC | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
| NCT02595905 | Phase II | Cisplatin Cisplatin + Veliparib | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | Active, not recruiting | USA | 1 |
| NCT02599363 | Phase I | Paclitaxel + Ribociclib | A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer | Completed | USA | 0 |
| NCT02605486 | Phase Ib/II | Bicalutamide + Palbociclib | Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | Active, not recruiting | USA | 0 |
| NCT02623972 | Phase II | Cyclophosphamide + Doxorubicin + Eribulin | A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | Active, not recruiting | USA | 0 |
| NCT02639026 | Phase I | Durvalumab + Tremelimumab | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | Active, not recruiting | USA | 0 |
| NCT02640508 | Phase II | Eribulin + Lenvatinib | Eribulin and Lenvatinib in Advanced Solid Tumors | Unknown status | USA | 0 |
| NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
| NCT02646319 | Phase I | Nab-rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
| NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
| NCT02721433 | FDA approved | Denosumab + pamidronate + Zoledronic acid | 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA) | Completed | CAN | 0 |
| NCT02725489 | Phase II | Durvalumab + FANG vaccine | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | Completed | USA | 0 |
| NCT02725541 | Phase II | Ado-trastuzumab emtansine | Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer | Withdrawn | USA | 0 |
| NCT02734004 | Phase Ib/II | Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) | Active, not recruiting | USA | GBR | FRA | 4 |
| NCT02746328 | Phase II | Enobosarm | Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass | Completed | USA | 0 |
| NCT02754011 | Phase I | Capecitabine + Ribociclib | Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative (GEP14-LEECAP) | Active, not recruiting | FRA | 0 |
| NCT02768337 | Phase Ib/II | Afatinib | Cambridge Brain Mets Trial 1 (CamBMT1) | Unknown status | GBR | 0 |
| NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
| NCT02874430 | Phase II | Doxycycline + Metformin | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | Active, not recruiting | USA | 0 |
| NCT02900469 | Phase 0 | Denosumab | Safety Study of Denosumab to Treat Breast Cancer | Completed | USA | 0 |
| NCT02926690 | Phase I | OTS167 | Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer | Recruiting | USA | 0 |
| NCT02939274 | Phase II | Verteporfin | An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer | Unknown status | USA | 0 |
| NCT02953782 | Phase Ib/II | Cetuximab + Hu5F9-G4 | Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer | Completed | USA | 0 |
| NCT02965885 | Phase I | Pimitespib | A Study of TAS-116 in Patients With Solid Tumors | Completed | USA | ITA | GBR | 0 |
| NCT02980341 | Phase Ib/II | Patritumab deruxtecan | Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer | Active, not recruiting | USA | 1 |
| NCT02985658 | Phase I | Cisplatin Veliparib Vinorelbine | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | No longer available | USA | 0 |
| NCT02999477 | Phase I | Pembrolizumab Nab-paclitaxel | A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03006172 | Phase I | GDC-0077 + Letrozole + Palbociclib GDC-0077 Fulvestrant + GDC-0077 GDC-0077 + Letrozole | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | Recruiting | USA | GBR | FRA | ESP | CAN | 0 |
| NCT03025035 | Phase II | Olaparib + Pembrolizumab | Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer | Recruiting | USA | 0 |
| NCT03032107 | Phase I | Ado-trastuzumab emtansine + Pembrolizumab | A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 | Active, not recruiting | USA | 0 |
| NCT03032406 | Phase II | Everolimus + Hydroxychloroquine Everolimus Hydroxychloroquine | CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03044730 | Phase II | Capecitabine + Pembrolizumab | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | Unknown status | USA | 0 |
| NCT03066947 | Phase Ib/II | Cyclophosphamide + Interferon alpha-2b + SV-BR-1-GM | SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer | Completed | USA | 0 |
| NCT03093350 | Phase II | MultiTAA-specific T cells | TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (TACTIC) | Active, not recruiting | USA | 0 |
| NCT03095352 | Phase II | Carboplatin + Pembrolizumab + Trastuzumab Carboplatin Carboplatin + Trastuzumab Carboplatin + Pembrolizumab | Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | Recruiting | USA | 0 |
| NCT03099174 | Phase I | Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab | This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. | Active, not recruiting | USA | FRA | ESP | 4 |
| NCT03101748 | Phase Ib/II | Neratinib + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel | 3HT With Taxol for Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03102606 | Phase II | Plinabulin Pegfilgrastim | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) | Completed | USA | 3 |
| NCT03154281 | Phase I | Everolimus + Niraparib | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast | Active, not recruiting | USA | 0 |
| NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
| NCT03207529 | Phase I | Alpelisib + Enzalutamide | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03237572 | Phase I | Pembrolizumab | Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48) | Terminated | USA | 0 |
| NCT03248492 | Phase II | Trastuzumab deruxtecan | A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 2 |
| NCT03262935 | Phase III | Capecitabine + Lapatinib Trastuzumab Duocarmazine Eribulin + Trastuzumab Capecitabine + Trastuzumab Trastuzumab + Vinorelbine | SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (TULIP) | Completed | USA | ITA | GBR | FRA | ESP | CAN | BEL | 4 |
| NCT03272334 | Phase Ib/II | HER2 BATs + Pembrolizumab | Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47) | Recruiting | USA | 0 |
| NCT03292536 | Phase I | Merestinib | Merestinib on Bone Metastases in Subjects With Breast Cancer | Terminated | USA | 0 |
| NCT03317405 | Phase I | Z-endoxifen HCl | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | Active, not recruiting | USA | 0 |
| NCT03328026 | Phase Ib/II | Cyclophosphamide + Interferon alpha-2b + Ipilimumab + SV-BR-1-GM Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM | Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab | Enrolling by invitation | USA | 0 |
| NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT03342417 | Phase II | Ipilimumab + Nivolumab | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | Terminated | USA | 0 |
| NCT03344965 | Phase II | Olaparib | Olaparib In Metastatic Breast Cancer | Recruiting | USA | 0 |
| NCT03363776 | Phase Ib/II | BMS-986277 BMS-986277 + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | Terminated | USA | CAN | 0 |
| NCT03367689 | Phase II | Olaparib | A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent (NOBROLA) | Terminated | ESP | 0 |
| NCT03394027 | Phase II | ONC201 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | Completed | USA | 0 |
| NCT03396211 | Phase I | Nivolumab + Rivoceranib | Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer | Completed | USA | 0 |
| NCT03400254 | Phase Ib/II | Gedatolisib + Hydroxychloroquine Hydroxychloroquine | A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") (GLACIER) | Withdrawn | USA | 0 |
| NCT03409458 | Phase Ib/II | Avelumab + Imifoplatin | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) | Completed | USA | 1 |
| NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Terminated | USA | GBR | FRA | ESP | 0 |
| NCT03412877 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer | Recruiting | USA | 0 |
| NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | 2 |
| NCT03448042 | Phase I | BTRC 4017A | A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 6 |
| NCT03449238 | Phase Ib/II | Pembrolizumab | Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients | Recruiting | USA | 0 |
| NCT03454529 | Phase II | Simvastatin | The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer | Completed | USA | 0 |
| NCT03476681 | Phase I | NEO-201 | QUILT-3.017: Study of NEO-201 in Solid Tumors | Recruiting | USA | 0 |
| NCT03518606 | Phase Ib/II | Durvalumab + Tremelimumab + Vinorelbine | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE) | Active, not recruiting | FRA | 0 |
| NCT03523572 | Phase I | Nivolumab + Trastuzumab deruxtecan | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | Unknown status | USA | ITA | GBR | FRA | ESP | DEU | BEL | 0 |
| NCT03565445 | Phase I | ASP1948 + Nivolumab ASP1948 | A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | CAN | 4 |
| NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
| NCT03602079 | Phase Ib/II | A166 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | Completed | USA | 0 |
| NCT03608020 | Phase Ib/II | BMX-001 | A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy | Recruiting | USA | 0 |
| NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
| NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
| NCT03632941 | Phase II | Pembrolizumab AVX901 + Pembrolizumab AVX901 | A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03635632 | Phase I | C7R-GD2.CART cells Cyclophosphamide + Fludarabine | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | Recruiting | USA | 0 |
| NCT03641755 | Phase Ib/II | Olaparib + Sapacitabine | Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03661424 | Phase I | HER2 BATs | BATs in Patients With Breast Cancer and Leptomeningeal Metastases | Terminated | USA | 0 |
| NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Recruiting | USA | AUS | 4 |
| NCT03717415 | Phase Ib/II | Carboplatin + Rebastinib | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | Unknown status | USA | 0 |
| NCT03719768 | Phase I | Avelumab | Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | Active, not recruiting | USA | 0 |
| NCT03734029 | Phase III | Trastuzumab deruxtecan Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 11 |
| NCT03742245 | Phase I | Olaparib + Vorinostat | Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | Recruiting | USA | 0 |
| NCT03763604 | Expanded access | Abemaciclib | Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | Available | ITA | GBR | ESP | CAN | AUS | 9 |
| NCT03786094 | Phase III | Eribulin Eribulin + POL6326 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | Terminated | USA | ITA | GBR | FRA | ESP | BEL | 7 |
| NCT03789097 | Phase Ib/II | CDX-301 + Pembrolizumab + Poly ICLC | Vaccination With Flt3L, Radiation, and Poly-ICLC | Recruiting | USA | 0 |
| NCT03796273 | Phase I | Ketoconazole | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases | Recruiting | USA | 0 |
| NCT03807765 | Phase I | Nivolumab | Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases | Active, not recruiting | USA | 0 |
| NCT03820141 | Phase II | Durvalumab + Pertuzumab + Trastuzumab | Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (DTP) | Recruiting | USA | 0 |
| NCT03821233 | Phase I | ZW49 | A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | Active, not recruiting | USA | CAN | AUS | 1 |
| NCT03847168 | Phase I | KN026 | KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer | Unknown status | USA | 0 |
| NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Active, not recruiting | USA | 0 |
| NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
| NCT03950570 | Phase I | ORIN1001 + Paclitaxel ORIN1001 | ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03955640 | Phase I | Olaparib | Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences | Unknown status | USA | 0 |
| NCT03964532 | Phase Ib/II | Talazoparib Avelumab + Talazoparib | TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03970382 | Phase I | NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Suspended | USA | 0 |
| NCT03982004 | Phase I | Imiquimod + Pembrolizumab + Sargramostim | Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer | Terminated | USA | 0 |
| NCT03995706 | Phase I | Sacituzumab govitecan-hziy | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | Active, not recruiting | USA | 0 |
| NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT04009044 | Phase II | Afimoxifene | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | Recruiting | USA | 0 |
| NCT04020575 | Phase I | huMNC2-CAR44 CAR T cells | Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) | Recruiting | USA | 0 |
| NCT04029922 | Phase I | MT-5111 | Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) | Terminated | USA | AUS | 1 |
| NCT04052971 | Phase Ib/II | ABN401 | To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation | Recruiting | AUS | 1 |
| NCT04092673 | Phase Ib/II | Fulvestrant + Zotatifin Zotatifin Sotorasib + Zotatifin Abemaciclib + Fulvestrant + Zotatifin Trastuzumab + Zotatifin | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin) | Recruiting | USA | 0 |
| NCT04115306 | Phase I | PMD-026 | Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
| NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
| NCT04134884 | Phase I | Decitabine and Cedazuridine + Talazoparib | Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer | Recruiting | USA | 0 |
| NCT04143711 | Phase Ib/II | DF1001 DF1001 + Pembrolizumab | Study of DF1001 in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | BEL | 2 |
| NCT04143789 | Phase Ib/II | AP-002 | Evaluation of AP-002 in Patients With Solid Tumors | Unknown status | USA | 0 |
| NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
| NCT04148937 | Phase I | LY3475070 LY3475070 + Pembrolizumab | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Completed | USA | GBR | AUS | 0 |
| NCT04158336 | Phase Ib/II | ZN-c3 Talazoparib + ZN-c3 Pembrolizumab + ZN-c3 | A Study of ZN-c3 in Participants With Solid Tumors | Recruiting | USA | 0 |
| NCT04169841 | Phase II | Durvalumab + Olaparib + Tremelimumab | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) | Recruiting | FRA | 0 |
| NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Terminated | USA | 0 |
| NCT04222413 | Phase I | Metarrestin | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT04235101 | Phase I | Niraparib + Trastuzumab Duocarmazine | Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | Completed | GBR | BEL | 1 |
| NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
| NCT04244552 | Phase I | ATRC-101 | First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Active, not recruiting | USA | 0 |
| NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
| NCT04257110 | Phase I | BB-1701 | A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors | Unknown status | USA | 1 |
| NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Active, not recruiting | USA | GBR | ESP | DEU | 1 |
| NCT04272801 | Phase II | Anastrozole Letrozole Tamoxifen Exemestane | Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (POWER) | Recruiting | USA | 0 |
| NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
| NCT04289805 | FDA approved | Letrozole | Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) (fAMHOPE) | Recruiting | ITA | FRA | BEL | 0 |
| NCT04319757 | Phase I | ACE1702 + Cyclophosphamide + Fludarabine | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | Recruiting | USA | 1 |
| NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | GBR | ESP | 0 |
| NCT04360941 | Phase I | Avelumab + Palbociclib | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (PAveMenT) | Recruiting | GBR | 0 |
| NCT04367675 | Phase I | INO-5401 INO-5401 + INO-9012 | INO 5401 Vaccination in BRCA1/2 Mutation Carriers | Recruiting | USA | 0 |
| NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 1 |
| NCT04418219 | Phase Ib/II | Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM | A Breast Cancer Vaccine (SV-BR-1-GM) in Combination With Pembrolizumab for the Treatment of Persistent, Recurrent, or Metastatic Breast Cancer | Withdrawn | USA | 0 |
| NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
| NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
| NCT04444427 | Phase Ib/II | GLR2007 | Evaluation of GLR2007 for Advanced Solid Tumors | Completed | USA | 0 |
| NCT04454528 | Phase Ib/II | Pembrolizumab | BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer | Recruiting | USA | 0 |
| NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Completed | USA | ITA | FRA | ESP | DEU | CAN | 8 |
| NCT04523857 | Phase II | Abemaciclib Abemaciclib + Hydroxychloroquine | ABemacicliB, HydroxYchloroquine, or the Combination to Target Minimal Residual Disease in Breast Cancer (ABBY) | Recruiting | USA | 0 |
| NCT04550494 | Phase II | Talazoparib | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Recruiting | USA | 0 |
| NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Active, not recruiting | ITA | 0 |
| NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Recruiting | USA | ESP | 0 |
| NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Active, not recruiting | USA | GBR | CAN | 1 |
| NCT04641247 | Phase II | Niraparib | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Active, not recruiting | USA | ITA | FRA | ESP | CAN | AUT | 2 |
| NCT04659603 | Phase II | SAR408701 Gemcitabine + SAR408701 | Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01) | Recruiting | USA | ESP | 8 |
| NCT04673448 | Phase I | Dostarlimab-gxly + Niraparib | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting | USA | 0 |
| NCT04683679 | Phase II | Olaparib + Pembrolizumab Pembrolizumab | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | Recruiting | USA | 0 |
| NCT04695847 | Phase I | M1231 | M1231 in Participants With Solid Tumors | Completed | USA | CAN | 0 |
| NCT04699630 | Phase II | Patritumab deruxtecan | A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer | Recruiting | USA | 0 |
| NCT04704661 | Phase I | Ceralasertib + Trastuzumab deruxtecan | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Recruiting | USA | 0 |
| NCT04714983 | Phase I | DNX-2440 | DNX-2440 for Resectable Colorectal Liver Metastasis | Recruiting | USA | 0 |
| NCT04717375 | Phase Ib/II | BND-22 | Study of BND-22 in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT04829604 | Phase II | ARX-788 | ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | Recruiting | USA | FRA | AUS | 1 |
| NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies | Recruiting | CAN | 0 |
| NCT04890613 | Phase I | CX-5461 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Recruiting | USA | CAN | 0 |
| NCT04899349 | Phase II | Alpelisib + Fulvestrant + Metformin Alpelisib + Dapagliflozin + Fulvestrant + Metformin | Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant (EPIK-B4) | Terminated | USA | 2 |
| NCT04947189 | Phase Ib/II | Dexamethasone + Docetaxel + Seviteronel | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer (4CAST) | Recruiting | AUS | 0 |
| NCT04957290 | Phase Ib/II | NOX66 | A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | Terminated | USA | 0 |
| NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | GBR | 0 |
| NCT05000294 | Phase Ib/II | Atezolizumab + Tivozanib | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Suspended | USA | 0 |
| NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | 0 |
| NCT05027139 | Phase Ib/II | Evorpacept + ZW25 | A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | Recruiting | USA | 0 |
| NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
| NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
| NCT05067972 | Phase I | PF-07260437 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) | Terminated | USA | 1 |
| NCT05076591 | Phase I | IMM2902 | IMM2902, a HER2/SIRPa Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05082025 | Phase II | Copanlisib + Fulvestrant | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | Recruiting | USA | 0 |
| NCT05091528 | Phase Ib/II | SBT6050 + Trastuzumab deruxtecan SBT6050 + Trastuzumab + Tucatinib Capecitabine + SBT6050 + Trastuzumab + Tucatinib | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | Terminated | USA | 0 |
| NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Recruiting | FRA | 1 |
| NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
| NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05123482 | Phase Ib/II | AZD8205 | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | Recruiting | USA | GBR | ESP | CAN | BEL | AUS | 8 |
| NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
| NCT05150652 | Phase II | Exemestane Tamoxifen Letrozole Anastrozole | Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer | Recruiting | USA | 0 |
| NCT05161195 | FDA approved | Fulvestrant + Ribociclib Ribociclib Ribociclib + Tamoxifen Goserelin + Ribociclib Letrozole + Ribociclib Anastrozole + Ribociclib | Roll-over Study to Allow Continued Access to Ribociclib | Recruiting | USA | ITA | ESP | 15 |
| NCT05180474 | Phase Ib/II | GEN1047 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Recruiting | USA | FRA | ESP | 2 |
| NCT05238922 | Phase I | INCB123667 | Study of INCB123667 in Subjects With Advanced Solid Tumors | Recruiting | USA | ITA | GBR | FRA | 3 |
| NCT05243641 | Phase Ib/II | Capmatinib + Neratinib | Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | Recruiting | USA | 0 |
| NCT05266105 | Phase I | OP-1250 + Palbociclib | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients | Recruiting | AUS | 0 |
| NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | AUS | 3 |
| NCT05288777 | Phase II | Capecitabine Ado-trastuzumab emtansine | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer (Breast53) | Recruiting | USA | 0 |
| NCT05305365 | Phase II | QBS10072S | Study Assessing QBS72S For Treating Brain Metastases of Breast Cancer | Recruiting | USA | 0 |
| NCT05306444 | Phase I | HBM7008 | HBM7008 -Study on Subjects With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
| NCT05307705 | Phase I | Abemaciclib + Anastrozole + LOXO-783 Abemaciclib + Exemestane + LOXO-783 Abemaciclib + Letrozole + LOXO-783 LOXO-783 + Paclitaxel Fulvestrant + LOXO-783 LOXO-783 + LY3484356 Abemaciclib + Fulvestrant + LOXO-783 Abemaciclib + LOXO-783 + LY3484356 Letrozole + LOXO-783 LOXO-783 Anastrozole + LOXO-783 Exemestane + LOXO-783 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01) | Recruiting | USA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
| NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Recruiting | USA | AUS | 0 |
| NCT05523947 | Phase Ib/II | YH32367 | Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor | Recruiting | AUS | 1 |
| NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
| NCT05633979 | Phase I | DS-3201b DS-3201b + Trastuzumab deruxtecan | Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer | Recruiting | USA | 0 |
| NCT05636215 | Phase Ib/II | Orismilast | A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
| NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
| NCT05655598 | Phase I | Palbociclib + Pimitespib | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Recruiting | USA | 0 |
| NCT05694715 | Phase I | Irinotecan + Niraparib | Combination Therapy in Cancers With Mutations in DNA Repair Genes | Recruiting | USA | 0 |
| NCT05700669 | Phase Ib/II | AsiDNA + Olaparib | Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors | Recruiting | USA | 0 |
| NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | BEL | 0 |
| NCT05731271 | Phase Ib/II | TST003 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | Recruiting | USA | 0 |
| NCT05765851 | Phase I | DS-1103a + Trastuzumab deruxtecan | A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | CAN | 0 |
| NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
| NCT05800964 | Phase I | AMG 305 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. | Recruiting | USA | FRA | ESP | DEU | AUS | 1 |
| NCT05807126 | Phase I | Hu5F9-G4 + Olaparib | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | Recruiting | USA | 0 |
| NCT05848739 | Phase I | ST316 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT05868226 | Phase I | Evorpacept + Trastuzumab deruxtecan | PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI) | Recruiting | USA | 0 |
| NCT05872295 | Phase I | IKS014 | IKS014 in Advanced Solid Tumors That Express HER2 | Recruiting | AUS | 0 |
| NCT05875168 | Phase Ib/II | DS-3939a | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT05877599 | Phase I | NT-175 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Recruiting | USA | 0 |
| NCT05892068 | Phase II | Tucatinib | A Study of Tucatinib Given Before Surgery to People With HER2 positive Cancers That Have Spread to the Brain | Recruiting | USA | 0 |
| NCT05932862 | Phase I | ISM3091 | First-in Human Phase I Study of ISM3091 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
| NCT05944276 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
| NCT05948865 | Phase I | CPO301 | A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT05985083 | Phase I | IMM47 | A Study Of IMM47 In Subjects With Advanced Solid Tumors | Recruiting | AUS | 0 |
| NCT06036121 | Phase I | ADRX-0706 | A Study of ADRX-0706 in Select Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06066424 | Phase I | Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Recruiting | USA | 0 |
| NCT06072612 | Phase III | Cyclophosphamide + Peg-interferon alfa-2a + Retifanlimab + SV-BR-1-GM Cyclophosphamide + Peg-interferon alfa-2a + SV-BR-1-GM | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC) | Recruiting | USA | 0 |
| NCT06100874 | Phase II | Sacituzumab govitecan-hziy + trastuzumab and hyaluronidase-oysk injection Sacituzumab govitecan-hziy + Trastuzumab | A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN) | Not yet recruiting | USA | 0 |
| NCT06130254 | Phase I | Adagrasib + Olaparib | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Not yet recruiting | USA | 0 |